MHRA issues FMD over HMS Wholesale Limited products
Posted: 24 March 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
A Class 4 falsified medicines directive (FMD) has been issued by the MHRA because medicines may have left the legal supply chain to be reintroduced later through HMS Wholesale Limited.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it is investigating how several medicines may have left the legal supply chain to be reintroduced via HMS Wholesale Limited. The company has now had its wholesale licence terminated.
According to the MHRA, the products seem to be legitimate with genuine batch numbers. However, since they may have been stolen in early 2019 and reintroduced later that same year, their efficacy and safety cannot be guaranteed. The agency stated that this is because they may have been transported or stored incorrectly during this time.
The advice from the MHRA is that if suppliers or patients have received any of these batches from HMS Wholesale Limited after May to August 2019, stocks must be checked and any remaining affected products quarantined, before notifying the Defective Medicines Report Centre (DMRC) or the MHRA.
